All In MedTech

Device Trial Radar · NCT02617563

5-Year Global Study on MAST™ Minimally Invasive Fusion Procedures to Treat Degenerative Lumbar Spine (MASTERS-D2)

A Prospective, 5-Year Global Study on MAST™ Minimally Invasive Fusion Procedures for the Treatment of the Degenerative Lumbar Spine

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

361

Actual

Start

Dec 2015

Primary completion

Nov 10, 2019

Study completion Nov 14, 2024

Sponsor

Lead sponsor
Medtronic Spinal and BiologicsPublic (MDT)
Sponsor type
Industry
First posted
Dec 1, 2015

More device trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is * to evaluate the effectiveness of MAST techniques for anterior/lateral and posterior approaches in Degenerative Disc Disease (DDD) patients with spondylolisthesis (≥ grade I). * To assess how single or double level MAST(Minimal Access Spinal Technologies) fusion procedures PLIF (Posterior Lumbar Interbody Fusion), TLIF (Transforaminal Lumbar Interbody Fusion), DLIF (Direct Lateral Interbody Fusion), OLIF (Oblique Lumbar Interbody Fusion), ALIF (Anterior Lumbar Interbody Fusion), or MIDLF (Midline Lumbar Interbody Fusion) are used in surgical practice and to describe long-term safety and effectiveness in a broad patient population of patients with degenerative lumbar disc disease .

Conditions

  • Intervertebral Disc Degeneration

Interventions

  • Minimally invasive lumbar fusionDevice

    Patients will receive a single or double level instrumented fusion using a minimally invasive/MAST™ PLIF, TLIF, DLIF, OLIF, ALIF or MIDLF surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon™ Spinal System, is mandatory in this study and will be either mini-open and/or percutaneous.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change (Preop-postop) of Disability, Oswestry Disability Index (ODI) at 3 Months as Compared to Baseline in DDD Patients With SpondylolisthesisTime frame: 3 months

Locations

27 sites in 17 countries. Site status is shown where the registry gives one.

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina

  • Kepler Universitatsklinikum

    Linz, Austria

  • AZ Delta

    Roeselare, Belgium

24 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.